Search Results - "Jochems, Anouk"

Palliative care needs of advanced cancer patients in the emergency department at the end of life: an observational cohort study by Verhoef, Mary-Joanne, de Nijs, Ellen, Horeweg, Nanda, Fogteloo, Jaap, Heringhaus, Christian, Jochems, Anouk, Fiocco, Marta, van der Linden, Yvette

“…Purpose Patients with advanced cancer commonly visit the emergency department (ED) during the last 3 months of life. Identification of these patients and their…”
Get full text

The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study by de Groot, Stefanie, Vreeswijk, Maaike P G, Welters, Marij J P, Gravesteijn, Gido, Boei, Jan J W A, Jochems, Anouk, Houtsma, Daniel, Putter, Hein, van der Hoeven, Jacobus J M, Nortier, Johan W R, Pijl, Hanno, Kroep, Judith R

“…Preclinical evidence shows that short-term fasting (STF) protects healthy cells against side effects of chemotherapy and makes cancer cells more vulnerable to…”
Get full text

Two patients with fluoropyrimidine overdose successfully managed without uridine triacetate by Kats, Chantal JAR, Jochems, Anouk, Jeurissen, Frank JF, Ledeboer, Aletta, van den Berg, Roland B

“…Introduction In this case report we describe two patients with 5-fluorouracil (5-FU) overdose due to an unintentional increased infusion rate in which…”
Get full text

DOSAGE study: protocol for a phase III non-inferiority randomised trial investigating dose-reduced chemotherapy for advanced colorectal cancer in older patients by Baltussen, Joosje C, van den Bos, Frederiek, Slingerland, Marije, Binda, Trishika R R, Liefers, Gerrit-Jan, van den Hout, Wilbert B, Fiocco, Marta, Verschoor, Arjan J, Cloos-van Balen, Marissa, Holterhues, Cynthia, Houtsma, Danny, Jochems, Anouk, Spierings, Leontine E A M M, van Bodegom-Vos, Leti, Mooijaart, Simon P, Gelderblom, Hans, Speetjens, Frank M, de Glas, Nienke A, Portielje, Johanneke E A

“…IntroductionTreating older adults with chemotherapy remains a challenge, given their under-representation in clinical trials and the lack of robust treatment…”
Get full text

Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands by Jochems, Anouk, Schouwenburg, Maartje G, Leeneman, Brenda, Franken, Margreet G, van den Eertwegh, Alfons J.M, Haanen, John B.A.G, Gelderblom, Hans, Uyl-de Groot, Carin A, Aarts, Maureen J.B, van den Berkmortel, Franchette W.P.J, Blokx, Willeke A.M, Cardous-Ubbink, Mathilde C, Groenewegen, Gerard, de Groot, Jan Willem B, Hospers, Geke A.P, Kapiteijn, Ellen, Koornstra, Rutger H, Kruit, Wim H, Louwman, Marieke W, Piersma, Djura, van Rijn, Rozemarijn S, ten Tije, Albert J, Vreugdenhil, Gerard, Wouters, Michel W.J.M, van der Hoeven, Jacobus J.M

“…Abstract Background In recent years, the treatment of metastatic melanoma has changed dramatically due to the development of immune checkpoint and…”
Get full text

Time trends in treatment patterns and survival of older patients with synchronous metastatic colorectal cancer in the Netherlands: A population-based study by Baltussen, Joosje C, de Glas, Nienke A, Liefers, Gerrit-Jan, Slingerland, Marije, Speetjens, Frank M, van den Bos, Frederiek, Cloos-van Balen, Marissa, Verschoor, Arjan J, Jochems, Anouk, Spierings, Leontine E A M M, Holterhues, Cynthia, van Gerven, Leander A, Mooijaart, Simon P, Portielje, Johanneke E A, Derks, Marloes G M

“…New treatment strategies have improved survival of metastatic colorectal cancer in trials. However, it is not clear whether older patients benefit from these…”
Get full text

Real-world Outcomes of First-line Anti-PD-1 Therapy for Advanced Melanoma: A Nationwide Population-based Study by van Zeijl, Michiel C.T., Haanen, John B.A.G., Wouters, Michel W.J.M., de Wreede, Liesbeth C., Jochems, Anouk, Aarts, Maureen J.B., van den Berkmortel, Franchette W.P.J., de Groot, Jan Willem B., Hospers, Geke A.P., Kapiteijn, Ellen W., Piersma, Djura, van Rijn, Rozemarijn S., Suijkerbuijk, Karijn P.M., ten Tije, Albert J., van der Veldt, Astrid A.M., Vreugdenhil, Gerard, van der Hoeven, Koos J.M., van den Eertwegh, Alfons J.M.

“…The efficacy of anti-programmed death-1 (PD-1) monotherapy for advanced melanoma has been established, but it is unknown to what extent patients benefit in the…”
Get full text

Switching to Immune Checkpoint Inhibitors upon Response to Targeted Therapy; The Road to Long-Term Survival in Advanced Melanoma Patients with Highly Elevated Serum LDH? by Schouwenburg, Maartje G, Suijkerbuijk, Karijn P M, Koornstra, Rutger H T, Jochems, Anouk, van Zeijl, Michiel C T, van den Eertwegh, Alfons J M, Haanen, John B A G, Aarts, Maureen Jb, Akkooi, Alexander C J van, Berkmortel, Franchette W P J van den, Groot, Jan Willem B de, Hospers, Geke A P, Kapiteijn, Ellen, Kruit, Wim H, Piersma, Djura, van Rijn, Rozemarijn S, Ten Tije, Albert J, Vreugdenhil, Gerard, Hoeven, Jacobus J M van der, Wouters, Michel W J M

“…The prognosis of patients with advanced melanoma has improved dramatically. However, the clinical outcomes of patients with highly elevated serum lactate…”
Get full text

Metastatic Uveal Melanoma: Treatment Strategies and Survival-Results from the Dutch Melanoma Treatment Registry by Jochems, Anouk, van der Kooij, Monique K, Fiocco, Marta, Schouwenburg, Maartje G, Aarts, Maureen J, van Akkooi, Alexander C, van den Berkmortel, Franchette W P J, Blank, Christian U, van den Eertwegh, Alfonsus J M, Franken, Margreet G, de Groot, JanWillem B, Haanen, John B A G, Hospers, Geke A P, Koornstra, Rutger H, Kruit, Wim H J, Louwman, Marieke, Piersma, Djura, van Rijn, Rozemarijn S, Suijkerbuijk, Karijn P M, Ten Tije, Albert J, Vreugdenhil, Gerard, Wouters, Michel W J M, van Zeijl, Michiel C T, van der Hoeven, Koos J M, Kapiteijn, Ellen

“…Uveal melanoma (UM) is the most common primary intraocular tumor in adults. Up to 50% of UM patients will develop metastases. We present data of 175 metastatic…”
Get full text

Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands by Franken, Margreet G, Leeneman, Brenda, Jochems, Anouk, Schouwenburg, Maartje G, Aarts, Maureen J.B, van Akkooi, Alexander C.J, van den Berkmortel, Franchette W.P.J, van den Eertwegh, Alfonsus J.M, de Groot, Jan Willem B, van der Hoeven, Koos J.M, Hospers, Geke A.P, Kapiteijn, Ellen, Koornstra, Rutger, Kruit, Wim H.J, Louwman, Marieke W.J, Piersma, Djura, van Rijn, Rozemarijn S, Suijkerbuijk, Karijn P.M, ten Tije, Albert J, Vreugdenhil, Gerard, Wouters, Michel W.J.M, van Zeijl, Michiel, Haanen, John B.A.G, Uyl-de Groot, Carin A

“…There is limited evidence on the costs associated with ipilimumab. We investigated healthcare costs of all Dutch patients with advanced cutaneous melanoma who…”
Get full text

Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands by Jochems, Anouk, Leeneman, Brenda, Franken, Margreet G, Schouwenburg, Maartje G, Aarts, Maureen J.B, van Akkooi, Alexander C.J, van den Berkmortel, Franchette W.P.J, van den Eertwegh, Alfonsus J.M, Groenewegen, Gerard, de Groot, Jan Willem B, Haanen, John B.A.G, Hospers, Geke A.P, Kapiteijn, Ellen, Koornstra, Rutger H, Kruit, Wim H.J, Louwman, Marieke W.J, Piersma, Djura, van Rijn, Rozemarijn S, ten Tije, Albert J, Vreugdenhil, Gerard, Wouters, Michel W.J.M, Uyl-de Groot, Carin A, van der Hoeven, Koos J.M

“…Phase III trials with ipilimumab showed an improved survival in patients with metastatic melanoma. We evaluated the use and safety of ipilimumab, and the…”
Get full text

Outcomes for systemic therapy in older patients with metastatic melanoma: Results from the Dutch Melanoma Treatment Registry by Jochems, Anouk, Bastiaannet, Esther, Aarts, Maureen J.B., van Akkooi, Alexander C.J., van den Berkmortel, Franchette W.P.J., Boers-Sonderen, Marye J., van den Eertwegh, Alfonsus J.M., de Glas, Nienke G., de Groot, Jan Willem B., Haanen, John B.A.G., Hospers, Geke A.P., van der Hoeven, Jacobus J.M., Piersma, Djura, van Rijn, Rozemarijn S., Suijkerbuijk, Karijn P.M., ten Tije, Albert J., van der Veldt, Astrid A.M., Vreugdenhil, Gerard, van Zeijl, Michiel C.T., Kapiteijn, Ellen, Wouters, Michel W.J.M

“…The incidence of metastatic melanoma is increasing in all ages. Multiple trials with targeted drugs and immune checkpoint inhibitors showed improved survival…”
Get full text

Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: prognostic factors associated with clinical outcomes by Schouwenburg, Maartje G, Jochems, Anouk, Leeneman, Brenda, Franken, Margreet G, van den Eertwegh, Alfons J M, Haanen, John B A G, van Zeijl, Michiel C T, Aarts, Maureen J, van Akkooi, Alexander C J, van den Berkmortel, Franchette W P J, Blokx, Willeke A M, de Groot, Jan Willem B, Hospers, Geke A P, Kapiteijn, Ellen, Koornstra, Rutger H, Kruit, Wim H, Louwman, Marieke W J, Piersma, Djura, van Rijn, Rozemarijn S, Suijkerbuijk, Karijn P M, Ten Tije, Albert J, Vreugdenhil, Gerard, Wouters, Michel W J M, van der Hoeven, Jacobus J M

“…The aim of this population-based study was to identify the factors associated with clinical outcomes in vemurafenib-treated patients and to evaluate outcomes…”
Get full text

Conjunctival Metastasis of a Cutaneous Melanoma by Brouwer, Niels J., Marinkovic, Marina, Jochems, Anouk, Kapiteijn, Ellen W., van Duinen, Sjoerd G., Haeseker, Barbara I., Jager, Martine J., Luyten, Gregorius P.M.

“…Purpose: To report a patient who presented with a conjunctival tumour as a first sign of distant metastasis of cutaneous melanoma. The patient was treated…”
Get full text

Recent treatment results for metastatic melanoma: data from the Dutch Melanoma Treatment Registry by van Zeijl, Michiel C T, van den Eertwegh, Alfons J M, Wouters, Michel W J M, Jochems, Anouk, Schouwenburg, Maartje G, Haanen, John B A G, Aarts, Maureen J, van den Berkmortel, Franchette W P J, de Groot, Jan W B, Hospers, Geke A P, Kapiteijn, Ellen, Koornstra, Rutger H, Piersma, Djura, van Rijn, Rozemarijn S, Suijkerbuijk, Karijn P M, Ten Tije, Albert J, van der Veldt, Astrid A M, Vreugdenhil, Gerard, van der Hoeven, Koos J M

“…To evaluate treatment strategies and survival of patients with unresectable stage IIIc or IV melanoma since the 2012 introduction of new drugs in the…”
Get more information